Developing new immune system boosters for tuberculosis treatment
Official title: Synthetic Macrophage-inducible C-type lectin (Mincle) Agonists: Screening, Design, and Formulation in combination Th17 adjuvants
Funded at Vaccine Formulation Institute (Ch) LTD · NIH-11202983 · Data updated 2026-11-12
This study is exploring new ways to boost the immune system's fight against tuberculosis by testing special compounds that help vaccines work better, and it's aimed at finding treatments that could eventually help people with this condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaccine Formulation Institute (Ch) LTD NIH-funded |
| Lab location | 1 site (Plan-Les-Ouates, Switzerland) |
| Project start | September 30, 2024 |
| Project end | September 29, 2029 |
| Funding year | 2024 |
| Award (this year) | $1,563,776 |
| NIH project number | 75N93024C00021-0-9999-1 |
| Project ID | NIH-11202983 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of tuberculosis or those who may benefit from enhanced vaccination strategies.
✕Less likely to help
Patients who are not at risk for tuberculosis or those who have already been effectively treated may not receive benefit from this research.
What this research studies
This research focuses on creating and testing new chemical compounds that activate a specific part of the immune system, known as Mincle agonists, to enhance the body's response against tuberculosis. By combining these compounds with various carriers and other immune stimulants, the researchers aim to identify effective adjuvants that can improve vaccine efficacy. The effectiveness of these lead adjuvants will be evaluated using animal models that mimic tuberculosis infection, providing insights into their potential use in humans.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and treatments for tuberculosis, improving patient outcomes.
How similar studies have gone: While the approach of using Mincle agonists is innovative, similar strategies in immunology have shown promise in enhancing vaccine responses, suggesting potential for success.
Where this research is happening
-
Vaccine Formulation Institute (Ch) LTD
Plan-Les-Ouates, Switzerland Active
Related research
Other NIH-funded projects on the same topics.
-
Developing a new liposome-based adjuvant for COVID-19 vaccines
This study is working on a new ingredient to boost the effectiveness of COVID-19 vaccines, making them stronger and more affordable, so that more people can benefit from better protection against the virus.
-
Developing a new liposome-based adjuvant for vaccines against SARS coronavirus
This study is working on a new, affordable ingredient to make vaccines stronger and more effective against certain viruses, with the hope that it will help create better vaccines for everyone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.